Healthcare >> CEO Interviews >> May 13, 2003
PERCY LOMAX has been Executive Chairman of ReGen Therapeutics Plc since June 4, 1998. He was brought in to commercialise the intellectual property of a Polish Institute. Mr. Lomax led the Ofex float in November 1998 and more importantly the flotation on AIM, which raised 5 million in March 2000. His responsibilities, in addition to chairing the Board, have been corporate strategy, corporate governance, fundraising and investor relations. During his time as Executive Chairman the company has been spending around 2.25 million each year. Mr. Lomax has been responsible for recruitment, salary packages and the general overall welfare of the staff. From January 11, 2001 to August 31, 2002 he was Chairman at Mediwatch Plc. Mr. Lomax was brought in after the public float at the request of the then brokers to steer the company through its initial public period. This period has now expired. As a non-Executive Chairman his duties were simply those commensurate with such a post and did not include budgetary responsibility. He formed Lomax Pharmaceutical Consulting on July, 1998, to carry on the work started at Teather & Greenwood. From August 2, 1995, to January 31, 1999, Mr. Lomax was co- founder and Director of Polymasc Pharmaceuticals Plc, developed to commercialise the intellectual property of a department of the Royal Free Hospital School of Medicine. This company was quoted on the AIM market in December 1995, and in summer 1999 was taken over by Valentis Incorporated. He was principally responsible for corporate governance, fundraising and investor relations. From January 1, 1995 to June 30, 1998 he was Corporate Healthcare Broker for Teather & Greenwood. During this time he was a leading person in the flotation of PolyMASC and Oxford Biomedica and the rescue rights issue of Proteus. His experience over the previous 10 years led him to believe he could do better on his own. From January 1, 1992, to December 31, 1994, he joined Robert Fleming Securities as Executive in charge of European pharmaceutical research, appointed Manager in April 1993. The work involved investment analysis and corporate broking. From January 6, 1990 to December 31, 1991 he was working in European and UK Pharmaceutical Sales and Research for Sheppards. His work involved all aspects of research and selling. From January 4, 1989, to May 31, 1990, he was a European Healthcare Analyst at Prudential Bache. From January 1987 to December 31, 1989, he was head of team researching and selling health care and chemicals at T.C. Coombs. he was promoted to become head of UK and European Sales and Research. He was in charge of a team of 10 with a budget of around 0.5 million. During this time he floated Medirace which subsequently became Medeva in August 1987, now part of the largest UK biotech company, Celltech. From October 1976 to September 1986 he was a Pharmaceutical and Chemical Analyst for Vivian Gray & Co. and became a general Partner and Head of Research. During this time he studied for the Stock Exchange exams, which he passed. From November 1973 to October 1976 he joined the firm of Hart Morris as a Pharmaceutical and Chemical Analyst directly from Fisons. From January 1970 to October 1973 he was a Corporate Planning Executive for Fisons. He co-wrote two major papers on the future of the agrochemical industry and Fisons' place in it and on the Holmes Chapel Plant (the major UK pharmaceutical plant). The conclusions of both, which were to get out of agrochemical and put more money into pharmaceuticals were rejected. From June 1967 to December 1969 he was Assistant to Commercial Intelligence Manager at Glaxo. This was primarily a market research department. During his period there he worked on the launch of Ventolin, at one time one of the 10 best selling drugs in the world and still a very important medicine. Mr. Lomax has a BSc Econ and is a Fellow of the Securities Institute. Profile
Mr. Lomax:
